Administración de Empresas
Departamento
![Foto de Administración de Empresas](/img/uploaded/F604C5D6976D4D722ACE810ACE624981.jpg)
![Foto de David Geffen School of Medicine at UCLA](/img/noimage_org.png)
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (4)
2022
-
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 8, Núm. 1, pp. 31-38
2021
-
Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease
Clinical Cardiology, Vol. 44, Núm. 10, pp. 1457-1466
2019
2016
-
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
Clinical Cardiology, Vol. 39, Núm. 6, pp. 313-320